Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 18Carcinoma, Transitional Cell 2Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Diseases 1Ureteral Neoplasms 1Transitional Cell Bladder Cancer 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Muscle Invasive Bladder Cancer 1Infiltrating Bladder Urothelial Carcinoma 1

Interventions

Specimen Handling 8pembrolizumab 7enfortumab vedotin 7Magnetic Resonance Spectroscopy 6avelumab 4Nivolumab 4Gemcitabine 3cabozantinib 2Ipilimumab 2Immunoglobulin G 2Disulfides 2Cisplatin 2Carboplatin 2CTLA-4 Antigen 2Biopsy 2vinflunine 1tremelimumab 1tocilizumab 1tamibarotene 1relatlimab 1eribulin 1erdafitinib 1durvalumab 1copanlisib 1atezolizumab 1Watchful Waiting 1Standard of Care 1Propranolol 1Practice Guidelines as Topic 1Plasmapheresis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ureteral Neoplasms × Cystectomy × 1 year × Clear all
NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Mayo Clinic

Phase 4 Recruiting
75 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡